SarahJordanNagleMD

PubMed

• 26 citations
  Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
  Jordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, Joshua A Hill, Vicky Wu, Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Victor A Chow, Ajay K Gopa...> ;Blood. 2022 Jun 30
• 32 citations
  Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies
  Sarah J. Nagle, Catherine R. Murphree, Philipp W. Raess, Levanto Schachter, Andy I. Chen, Brandon Hayes-Lattin, Eneida R. Nemecek, Richard T. Maziarz> ;American Journal of Hematology. 2021 Apr 1
• 27 citations
  Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis
  Adam Kittai, Ying Huang, Max J. Gordon, Nathan Denlinger, Agrima Mian, Lindsey Fitzgerald, Jennifer Bishop, Sarah J. Nagle, Deborah M. Stephens, Samantha Jaglowski, Br...> ;Transplantation and Cellular Therapy. 2021 Jan 1
• Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma - The Oregon Health and Science University Experience.
  Derek Galligan, Staci Williamson, Jessie Myers, Rebecca Silbermann, Eva Medvedova, Sarah J. Nagle, Levanto Schachter, Andy I. Chen, Emma C. Scott, Richard T. Maziarz> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 5
• 1 citations
  Preparing Trainees to Deliver High-Value and Cost-Conscious Care in Hematology.
  Sarah J. Nagle, Erin Aakhus> ;Current Hematologic Malignancy Reports. 2020 Jul 6
• 29 citations
  Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
  Jakub Svoboda, Steven M. Bair, Daniel J. Landsburg, Sunita D. Nasta, Sarah J. Nagle, Stefan K. Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren E. Strel...> ;Haematologica. 2020 May 15
• 1 citations
  Correction to: Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment.
  Jessica Rice, Sarah J. Nagle, Julie Randall, Holly E. Hinson> ;Current Treatment Options in Neurology. 2019 Aug 9
• 55 citations
  Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment.
  Jessica Rice, Sarah J. Nagle, Julie Randall, Holly E. Hinson> ;Current Treatment Options in Neurology. 2019 Jul 20
• 19 citations
  Postural sway, falls, and self-reported neuropathy in aging female cancer survivors
  Peter C. Fino, Fay B. Horak, Mahmoud El-Gohary, Carolyn Guidarelli, Mary E. Medysky, Sarah J. Nagle, Kerri M. Winters-Stone> ;Gait & Posture. 2019 Jan 17
• 41 citations
  Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.
  Nirav N. Shah, Sarah J. Nagle, Drew A. Torigian, Michael D. Farwell, Wei-Ting Hwang, Noelle V. Frey, Sunita D. Nasta, Daniel J. Landsburg, Anthony R. Mato, Carl H. Jun...> ;Cytotherapy. 2018 Dec 1
• 10 citations
  Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation.
  Sarah J. Nagle, Ran Reshef, Donald E. Tsai> ;Clinics in Chest Medicine. 2017 Dec 1
• 13 citations
  Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS.
  Sarah J. Nagle, Nirav N. Shah, Alex Ganetsky, Daniel J. Landsburg, Sunita D. Nasta, Anthony R. Mato, Stephen J. Schuster, Ran Reshef, Donald E. Tsai, Jakub Svoboda> ;International Journal of Hematologic Oncology. 2017 Dec 1
• 28 citations
  Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospect...
  Steven M. Bair, Lauren E. Strelec, Sarah J. Nagle, Sunita D. Nasta, Daniel J. Landsburg, Anthony R. Mato, Alison W. Loren, Stephen J. Schuster, Edward A. Stadtmauer, J...> ;American Journal of Hematology. 2017 Sep 1
• 7 citations
  The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
  Sarah J. Nagle, Alfred L. Garfall, Edward A. Stadtmauer> ;Cancer Journal. 2016 Jan 1
• 12 citations
  The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.
  Sarah J. Nagle, Elise A. Chong, Seble Chekol, Nirav N. Shah, Sunita D. Nasta, Eli Glatstein, John P. Plastaras, Drew A. Torigian, Stephen J. Schuster, Jakub Svoboda> ;Cancer Medicine. 2015 Jan 1
• 101 citations
  Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
  Sarah J. Nagle, Kaitlin Woo, Stephen J. Schuster, Sunita D. Nasta, Edward A. Stadtmauer, Rosemarie Mick, Jakub Svoboda> ;American Journal of Hematology. 2013 Oct 1
• 59 citations
  A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
  Fabian A. Mendoza, Sarah J. Nagle, Jason B. Lee, Sergio A. Jimenez> ;The Journal of Rheumatology. 2012 Jun 1
• Join now to see all